IMMUNIC, INC.
Close on Oct 19, 2026
- Market cap
- $297.17M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Earnings
Next report expected Nov 12, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | Before market open | – | $-1.08 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | – | $-0.24 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | $-0.21 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | Before market open | – | $-0.30 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 22, 2024 | Before market open | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 14, 2023 | Before market open | – | $-0.51 | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 3, 2023 | Before market open | – | $-0.54 | – |
Press releases
Announcements Immunic filed with the SEC
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Board with Financial, Capital Markets and Commercial Leadership Expertise as the Company Approaches Pivotal Phase 3 ENSURE Readout in
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
Erik Lundgren as Chief Executive Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Executive Michael W. Bonney as Chair of the Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Michael A. Panzara, M.D., M.P.H.,
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Immunic, Inc. Announces 1-for-10 Reverse
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Immunic Regains Compliance with Nasdaq Minimum
Other events · EX-99.1 to Form 8-K
of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Immunic, Inc. Reports Year-End 2025 Financial
Results of operations · EX-99.1 to Form 8-K
Immunic Announces Oversubscribed Private Placement
Material agreement · Unregistered share sale · Executive or director change · Other events · EX-99.1 to Form 8-K
Immunic, Inc. Reports Third Quarter 2025
Results of operations · EX-99.1 to Form 8-K
Calcium Data at the 41 st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis
Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Other events · EX-99.2 to Form 8-K
Immunic, Inc. Reports Second Quarter 2025
Results of operations · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Other events · EX-99.2 to Form 8-K
Immunic, Inc. Announces Pricing of Oversubscribed
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Immunic, Inc. Announces Proposed Public Offering
Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Other events · EX-99.2 to Form 8-K
Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Other events · EX-99.2 to Form 8-K
Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Other events · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Immunic, Inc. Reports Third Quarter 2024
Results of operations · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Other events · EX-99.2 to Form 8-K
Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis
Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Other events · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Jason Tardio, Experienced Multiple Sclerosis Drug Commercialization Executive, Formerly with Novartis and Biogen, Appointed Chief Operating
Results of operations · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Other events · EX-99.2 to Form 8-K
Substantially Bolstered Balance Sheet Through a Three-Tranche Private Placement Totaling Up to $240 Million, Extending Cash Runway Into
Results of operations · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Other events · EX-99.2 to Form 8-K
End 2023 Financial Results and Provides Corporate Update
Results of operations · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Other events · EX-99.2 to Form 8-K